MedReleaf Corp. Announces Filing of Preliminary Prospectus for Initial Public Offering of Common Shares

MARKHAM, ONTARIO--(Marketwired - April 19, 2017) -

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

MedReleaf Corp. (MedReleaf or the Company) announced today that it has filed a preliminary prospectus with the securities regulatory authorities in each of the provinces and territories of Canada, in connection with a proposed initial public offering (the Offering) of common shares (the Common Shares). The Offering is expected to include a treasury offering of Common Shares by the Company and a secondary offering of Common Shares by certain shareholders. The number of Common Shares to be sold and the price per common share have not yet been determined. A copy of the preliminary prospectus is available on SEDAR (www.sedar.com).

The Offering will be made through a syndicate of underwriters co-led by GMP Securities L.P., who will also act as sole bookrunner.

The preliminary prospectus has not yet become final for the purpose of the sale of securities. Information contained in the preliminary prospectus may not be complete and may have to be amended. The securities may not be sold until a receipt for a final prospectus is obtained from the securities regulatory authorities.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The subordinate voting shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the U.S. Securities Act) or any state securities laws. Accordingly, the Common Shares may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of MedReleaf in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About MedReleaf Corp.

MedReleaf is a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"), based in Markham, Ontario. From its Markham facility, the Company produces and sells its dried cannabis and cannabis oil products, including cannabis oil capsules, to patients registered under the ACMPR. The first and only ISO 9001 certified cannabis producer in Canada, MedReleaf is an analytically-driven organization focused on patient care, scientific innovation, and advancing the understanding of the therapeutic benefits of cannabis.

A preliminary prospectus containing important information relating to these securities has been filed with securities commissions or similar authorities in certain jurisdictions of Canada. The preliminary prospectus is still subject to completion or amendment. Copies of the preliminary prospectus may be obtained from GMP Securities L.P. by contacting ecm@gmpsecurities.com. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued.